Psikofarmakoloji: Psikiyatri Hemşireleri Neleri, Neden Bilmeli?

Year 2024, Volume: 11 Issue: 2, 178 - 186, 28.08.2024

Merve Murat , Leyla Küçük

https://doi.org/10.31125/hunhemsire.1169736

Abstract

Psikiyatrik bozuklukların tedavisinde yararlanılan psikofarmakolojik ilaçların sistemik etkileri mevcuttur. Sistemik etkilerin anlaşılması ve bireyde davranış değişikliklerinin gözlenmesi için ruh sağlığı profesyonellerinin temel psikofarmakolojik bilgiye sahip olması gerekmektedir. Psikiyatri hemşireleri ilacın sadece uygulama adımında değil, ilacın yarattığı etkilerin gözlenmesinde de önemli roller üstlenmektedir. Bu nedenle, psikiyatri hemşireleri psikofarmakolojik ilaçlar ile ilgili temel ve güncel bilgilere hâkim olmalıdır. Bu temel bilgiler, hastanın tedavi ve bakımının profesyonel bir şekilde yönetimine fayda sağlayacağı için psikiyatri hemşirelerine yol gösterici olacaktır.

Keywords

Farmakokinetik, psikofarmakoloji, psikiyatri hemşireliği

Psychopharmacology: What Should Psychiatric Nurses Know and Why?

Abstract

There are systemic effects of psychopharmacological agents used in the psychiatric disorders’ treatment. Mental health professionals must have basic psychopharmacological knowledge to understand the systemic effects and observe behavioral changes in the individual. Psychiatric nurses who spend the most time with patients play an essential role not only in the drug’s administration but also in observing its effects. For this reason, psychiatric nurses should have basic and up-to-date knowledge of psychopharmacological agents. This basic information will guide psychiatric nurses as it will benefit the professional management of the patient's treatment and care.

Keywords

Pharmacokinetic, psychopharmacology, psychiatric nursing

References

• 1. Britannica TE. Psychopharmacology [Internet]. 2019 [Erişim Tarihi 20 Mart 2022]. Erişim adresi: https://www.britannica.com/science/psychopharmacology
• 2. Braslow JT, Marder SR. History of psychopharmacology. Annu Rev Clin Psychol. 2019;15:25-50.
• 3. Institute of Health Metrics and Evaluation. Global Health Data Exchange [Internet]. 2022 [Erişim Tarihi 14 Mayıs 2022]. Erişim adresi: https://vizhub.healthdata.org/gbd-results/
• 4. World Health Organization. Mental health and COVID-19: Early evidence of the pandemic’s impact [Internet]. 2022 [Erişim Tarihi 14 Mayıs 2022]. Erişim adresi: https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1
• 5. Demiralp M. Psychiatric nursing practices in psychopharmacological treatments. Turkiye Klinikleri J Psychiatr Nurs-Special Topics. 2016;2(3):87-99.
• 6. Dökmeci İ. Farmakoloji ilaçlar ve etkileri. İstanbul: Alfa Yayınları; 2007.
• 7. Soygür HT. Psikofarmakolojinin tarihsel gelişimi. Yüksel N, Tural Ü, Soygür HT, editörler. Temel Psikofarmakoloji. Ankara: Türk Psikiyatri Derneği; 2005; p. 1-13.
• 8. Howland RH. Serendipity and psychopharmacology. J Psychosoc Nurs Ment Health Serv. 2010;48(10):9-12.
• 9. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495-500.
• 10. Robinson E. Psychopharmacology: From serendipitous discoveries to rationale design, but what next? Brain Neurosci Adv. 2018;22(2):1–11.
• 11. Kunz E. Henri Laborit and the inhibition of action. Dialogues Clin Neurosci. 2014;16(1):113-7.
• 12. Howland RH. The challenges of clinical psychopharmacological management. J Psychosoc Nurs Ment Health Serv. 2012;50(5):17-20.
• 13. Currie GM. Pharmacology, Part 1: Introduction to pharmacology and pharmacodynamics. J Nucl Med Technol. 2018;46(2):81-6.
• 14. Currie GM. Pharmacology, Part 2: Introduction to pharmacokinetics. J Nucl Med Technol. 2018;46(3):221-30.
• 15. Rosenjack Burchum J, Rosenthal LD. Lehne’s pharmacology for nursing care. St. Louis, Missouri: Elsevier; 2019.
• 16. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
• 17. Carlson NR. Foundations of physiological psychology. Boston, MA:Pearson Education; 2006.
• 18. Sawa A, Snyder SH. Schizophrenia: neural mechanisms for novel therapies. Mol Med. 2003;9(1-2):3-9.
• 19. Sheffler ZM, Reddy V, Pillarisetty LS. Physiology, neurotransmitters. [Internet]. 2022 [Erişim Tarihi 8 Haziran 2022]. Erişim adresi: https://www.ncbi.nlm.nih.gov/books/NBK539894/
• 20. Kempadoo KA, Mosharov EV, Choi SJ, Sulzer D, Kandel ER. Dopamine release from the locus coeruleus to the dorsal hippocampus promotes spatial learning and memory. Proc Natl Acad Sci USA. 2016;113(51):14835-40.
• 21. Patriquin MA, Bauer IE, Soares JC, Graham DP, Nielsen DA. Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet. 2015;25(5):181-93.
• 22. Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019;39(1):31-59.
• 23. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182-217.
• 24. Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5:47.
• 25. Saboory E, Ghasemi M, Mehranfard N. Norepinephrine, neurodevelopment and behavior. Neurochem Int. 2020;135:104706.
• 26. Kumar P, Deb PK. Frontiers in pharmacology of neurotransmitters. Singapore: Springer; 2020.
• 27. Berridge CW, Schmeichel BE, España RA. Noradrenergic modulation of wakefulness/arousal. Sleep Med Rev. 2012;16(2):187-97. 28. Palacios JM. Serotonin receptors in brain revisited. Brain Res. 2016;1645:46-9.
• 29. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-66.
• 30. Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Mol Brain. 2017;10(1):28.
• 31. Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76(1):116-29.
• 32. Niwa Y, Kanda GN, Yamada RG, Shi S, Sunagawa GA, Ukai-Tadenuma M, et al. Muscarinic acetylcholine receptors Chrm1 and Chrm3 are essential for REM sleep. Cell Rep. 2018;24(9):2231-2247.e7.
• 33. Haam J, Yakel JL. Cholinergic modulation of the hippocampal region and memory function. J Neurochem. 2017;142(2):111-21.
• 34. Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther. 2013;137(1):22-54.
• 35. Brown DA. Muscarinic acetylcholine receptors (mAChRs) in the nervous system: some functions and mechanisms. J Mol Neurosci. 2010;41(3):340-6.
• 36. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88(3):1183-241.
• 37. Obara I, Telezhkin V, Alrashdi I, Chazot PL. Histamine, histamine receptors, and neuropathic pain relief. Br J Pharmacol. 2020;177(3):580-99.
• 38. Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE. Structure of a human synaptic GABAA receptor. Nature. 2018;559(7712):67-72.
• 39. Frangaj A, Fan QR. Structural biology of GABAB receptor. Neuropharmacology. 2018;136(Pt A):68-79.
• 40. Bowery NG, Smart TG. GABA and glycine as neurotransmitters: a brief history. Br J Pharmacol. 2006;147(1):S109-19.
• 41. Dutertre S, Becker CM, Betz H. Inhibitory glycine receptors: an update. J Biol Chem. 2012;287(48):40216-23.
• 42. Ito S. GABA and glycine in the developing brain. J Physiol Sci. 2016;66(5):375-9.
• 43. Jansson LC, Åkerman KE. The role of glutamate and its receptors in the proliferation, migration, differentiation and survival of neural progenitor cells. J Neural Transm (Vienna). 2014;121(8):819-36.
• 44. Nakanishi M, Koyama A, Ito H, Kurita H, Higuchi T. Nurses' collaboration with physicians in managing medication improves patient outcome in acute psychiatric care. Psychiatry Clin Neurosci. 2006;60(2):196-203.
• 45. Brauer R, Alfageh B, Blais JE, Chan EW, Chui CSL, Hayes JF, et al. Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study. Lancet Psychiatry. 2021;8(12):1071-82.
• 46. Virgolesi M, Pucciarelli G, Colantoni AM, D'Andrea F, Di Donato B, Giorgi F, et al. The effectiveness of a nursing discharge programme to improve medication adherence and patient satisfaction in the psychiatric intensive care unit. J Clin Nurs. 2017;26(23-24):4456-66.
• 47. Loots E, Goossens E, Vanwesemael T, Morrens M, Van Rompaey B, Dilles T. Interventions to improve medication adherence in patients with schizophrenia or bipolar disorders: A Systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(19):10213.
• 48. Song YO, Kimi H, Nam Y, Choe K, Ha J. Effects of a competency-based education program for inpatient psychiatric nurses: A pre-post intervention study. J Korean Acad Psychiatr Ment Health Nurs. 2022;31(1): 80–7.
• 49. Parikh SV, Bostwick JR, Bastida M, Taubman DS. Improving psychiatric medication use through the Michigan e-psychopharmacology course for nurse practitioners: A pre-post/follow-up study. Perspect Psychiatr Care. 2020;56(3):547-53.
• 50. DiGiacomo JN, Robert LS. Managing malpractice risks during psychopharmacologic treatment. The Evolution of Forensic Psychiatry: History, Current Developments, Future Directions. 2015;181-192.